Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Cited by (1,049)

Items 401–500 of 1,049

1. Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation.
   Sos, Martin L., Rode, Haridas B., Heynck, Stefanie, Peifer, Martin, Fischer, Florian, Klüter, Sabine, Pawar, Vijaykumar G., Reuter, Cecile, Heuckmann, Johannes M., Weiss, Jonathan et al. · 2010 · Cancer Research
2. Ultra-sensitive detection of the pretreatment EGFR T790M mutation in non-small cell lung cancer patients with an EGFR-activating mutation using droplet digital PCR
   Watanabe, Masaru, Kawaguchi, Tomoya, Isa, Shun-ichi, Ando, Masahiko, Tamiya, Akihiro, Kubo, Akihito, Saka, Hideo, Takeo, Sadanori, Adachi, Hirofumi, Tagawa, Tsutomu et al. · 2015 · Clinical Cancer Research
3. Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib
   Stéphanie Héon, Beow Yong Yeap, Gregory Joseph Britt, Daniel Botelho Costa, Michael S. Rabin, David Michael Jackman, Bruce Evan Johnson · 2010 · Clinical Cancer Research
4. Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial
   Zhijie Wang, Ying Cheng, Tongtong An, Hongjun Gao, Kai Wang, Qing Hua Zhou, Yanping Hu, Yong Song, Cuimin Ding, Feng Peng et al. · 2018 · The Lancet Respiratory Medicine
5. Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002
   Couraud, Sébastien, Vaca-Paniagua, Felipe, Villar, Stéphanie, Oliver, Javier, Schuster, Tibor, Blanché, Hélène, Girard, Nicolas, Trédaniel, Jean, Guilleminault, Laurent, Gervais, Radj et al. · 2014 · Clinical Cancer Research
6. Cancer pharmacogenomics: strategies and challenges
   Heather E. Wheeler, Michael L. Maitland, M. Eileen Dolan, Nancy Jean Cox, Mark J. Ratain · 2012 · Nature Reviews Genetics
7. Epidermal growth factor receptor (EGFR): A rising star in the era of precision medicine of lung cancer
   Xiaomin Liu, Ping Wang, Caiyan Zhang, Zhongliang Ma · 2017 · Oncotarget
8. Refining the Diagnosis and EGFR Status of Non-small Cell Lung Carcinoma in Biopsy and Cytologic Material, Using a Panel of Mucin Staining, TTF-1, Cytokeratin 5/6, and P63, and EGFR Mutation Analysis
   Andrew Gordon Nicholson, David González de Castro, Pallav L. Shah, Matthew J. Pynegar, Manjiri Deshmukh, Alexandra J. Rice, Sanjay Popat · 2010 · Journal of Thoracic Oncology
9. The Evolving War on Cancer
   Daniel A. Haber, Nathanael S. Gray, Jose M Baselga · 2011 · Cell
10. Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer
    Vassiliki A. Papadimitrakopoulou · 2012 · Journal of Thoracic Oncology
11. PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis
    Nina Ilić, Tamara Utermark, Hans R. Widlund, Thomas M. Roberts · 2011 · Proceedings of the National Academy of Sciences
12. Personalized medicine using DNA biomarkers: a review
    Andreas Ziegler, Armin Koch, Katja Krockenberger, Anika Großhennig · 2012 · Human Genetics
13. Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis
    Luo, Jie, Shen, Li, Zheng, Di · 2014 · Scientific Reports
14. Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib
    Naidoo, Jarushka, Sima, Camelia S., Rodriguez, Katherine, Busby, Natalie, Nafa, Khedoudja, Ladanyi, Marc, Riely, Gregory J., Kris, Mark G., Arcila, Maria E., Yu, Helena A. · 2015 · Cancer
15. Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic
    Timothy Anthony Yap, Shahneen Kaur Sandhu, Craig P. Carden, Johann Sebastian De Bono · 2011 · CA A Cancer Journal for Clinicians
16. Osimertinib-Induced Cardiotoxicity
    Kartik Anand, Joe Ensor, Barry H. Trachtenberg, Eric Bernicker · 2019 · JACC CardioOncology
17. Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum: From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer
    Kōichi Goto, Yukito Ichinose, Yuichiro Ohe, Nobuyuki Yamamoto, Shunichi Negoro, Kazuto Nishio, Yohji Itoh, Haiyi Jiang, Emma L. Duffield, Rose McCormack et al. · 2011 · Journal of Thoracic Oncology
18. Nasopharyngeal carcinoma: The next challenges
    Albiruni R. Abdul Razak, Lillian L. Siu, Fei‐Fei Liu, Emma Ito, Brian O’Sullivan, Kelvin Chan · 2010 · European Journal of Cancer
19. Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR -Mutant Lung Cancer
    Erin M. Tricker, Chunxiao Xu, Sharmeen Uddin, Marzia Capelletti, Dalia Ercan, Atsuko Ogino, Christine A. Pratilas, Neal X. Rosen, Nathanael S. Gray, Kwok‐Kin Wong et al. · 2015 · Cancer Discovery
20. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients
    J.L. Kuiper, Daniëlle A.M. Heideman, Erik Thunnissen, M.A. Paul, A.W. van Wijk, Pieter E. Postmus, Egbert Frederik Smit · 2014 · Lung Cancer
21. Genomic Profiling of Advanced Non–Small Cell Lung Cancer in Community Settings: Gaps and Opportunities
    Martin E Gutierrez, Kelly Choi, Richard Burnham Lanman, Edward J. Licitra, Stan M Skrzypczak, Ruth Pe Benito, Tommy Wu, Srikesh G. Arunajadai, Sukhi Kaur, Harry D. Harper et al. · 2017 · Clinical Lung Cancer
22. Demographics, Safety and Quality, and Prognostic Information in Both the Seventh and Eighth Editions of the TNM Classification in 18,973 Surgical Cases of the Japanese Joint Committee of Lung Cancer Registry Database in 2010
    Jiro Okami, Yasushi Shintani, Meinoshin Okumura, Hiroyuki Ito, Takashi Ohtsuka, Shinichi Toyooka, Takeshi Mori, Shun-ichi I. WATANABE, Hiroshi Date, Kohei Yokoi et al. · 2018 · Journal of Thoracic Oncology
23. CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer
    Man Zhang, Wei Zhong Yang, Peng Wang, Yu Deng, Yuting Dong, Fangfang Liu, Rui Huang, Peng Zhang, Yaqi Duan, Xindong Liu et al. · 2020 · Nature Communications
24. The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)
    Aisner, Dara L., Sholl, Lynette M., Berry, Lynne D., Rossi, Michael R., Chen, Heidi, Fujimoto, Junya, Moreira, Andre L., Ramalingam, Suresh S., Villaruz, Liza C., Otterson, Gregory A. et al. · 2018 · Clinical Cancer Research
25. Clinical Pharmacokinetics and Pharmacodynamics of Afatinib
    Wind, Sven, Schnell, David, Ebner, Thomas, Freiwald, Matthias, Stopfer, Peter · 2017 · Clinical Pharmacokinetics
26. Trifluoperazine, an Antipsychotic Agent, Inhibits Cancer Stem Cell Growth and Overcomes Drug Resistance of Lung Cancer
    Chi‐Tai Yeh, Alexander T.H. Wu, Peter Mu‐Hsin Chang, Kuan‐Yu Chen, Chia-Ning Yang, Shuenn‐Chen Yang, Chao‐Chi Ho, Chun‐Chi Chen, Yu-Lun Kuo, Pei Ying Lee et al. · 2012 · American Journal of Respiratory and Critical Care Medicine
27. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study
    Kenneth John O'Byrne, Ulrich Gatzemeier, Igor Bondarenko, Carlos H. Barrios, Corinna Eschbach, Uwe M. Martens, Yevhen Hotko, C. Kortsik, Luis G Paz-Ares, Jose R. Pereira et al. · 2011 · The Lancet Oncology
28. Dual IHC and FISH Testing for ALK Gene Rearrangement in Lung Adenocarcinomas in a Routine Practice: A French Study
    Anne Mc Leer, Denis Moro‐Sibilot, A. Melis, Dimitri Salameire, Christine Lefebvre, Françoise Ceccaldi, Florence de Fraipont, Elisabeth M. Brambilla, Sylvie Lantuéjoul · 2011 · Journal of Thoracic Oncology
29. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC)
    Ping‐Chih Hsu, David M. Jablons, Cheng‐Ta Yang, Liang You · 2019 · International Journal of Molecular Sciences
30. Precision Management of Advanced Non–Small Cell Lung Cancer
    Ching‐Yao Yang, James Chih‐Hsin Yang, Pan‐Chyr Yang · 2020 · Annual Review of Medicine
31. NF-κB-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer
    Blakely, Collin M., Pazarentzos, Evangelos, Olivas, Victor, Asthana, Saurabh, Yan, Jenny Jiacheng, Tan, Irena, Hrustanovic, Gorjan, Chan, Elton, Lin, Luping, Neel, Dana S. et al. · 2015 · Cell Reports
32. FGFR1 Amplification in Squamous Cell Carcinoma of The Lung
    Rebecca Suk Heist, Mari A. Mino-Kenudson, Lecia Van Dam Sequist, Swathi Tammireddy, Laura Morrissey, David C. Christiani, Jeffrey A. Engelman, Anthony John Iafrate · 2012 · Journal of Thoracic Oncology
33. Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer
    Kenichi Suda, Isao Murakami, Tatsuya Katayama, Kenji Tomizawa, Hirotaka Osada, Yoshitaka Sekido, Yoshihiko Maehara, Yasushi Yatabe, Tetsuya Mitsudomi · 2010 · Clinical Cancer Research
34. Highly Sensitive Droplet Digital PCR Method for Detection of EGFR-Activating Mutations in Plasma Cell–Free DNA from Patients with Advanced Non–Small Cell Lung Cancer
    Guanshan Zhu, Xin Ye, Zhengwei Dong, Ya Lu, Yun Sun, Yi Liu, Rose McCormack, Yi Gu, Xiaoqing Liu · 2015 · Journal of Molecular Diagnostics
35. Integrative and Comparative Genomic Analysis of Lung Squamous Cell Carcinomas in East Asian Patients
    Young-Wook Kim, Peter S. Hammerman, Jaegil Kim, Ji-ae Yoon, Yoomi Lee, Jong‐Mu Sun, Matthew D. Wilkerson, Chandra Sekhar Pedamallu, Kristian Cibulskis, Yeong Kyung Yoo et al. · 2013 · Journal of Clinical Oncology
36. Cancer Genomics: Diversity and Disparity Across Ethnicity and Geography
    Daniel S.W. Tan, Tony S.K. Mok, Timothy Richard Rebbeck · 2015 · Journal of Clinical Oncology
37. Prevalence and detection of low-allele-fraction variants in clinical cancer samples
    Hyun‐Tae Shin, Yoon‐La Choi, Jae Won Yun, Nayoung K. D. Kim, Sook‐Young Kim, Hyo Jeong Jeon, Jae‐Yong Nam, Chung Lee, Daeun Ryu, Sang Cheol Kim et al. · 2017 · Nature Communications
38. Lung cancer in never smokers—the East Asian experience
    Fei Zhou, Caicun Zhou · 2018 · Translational Lung Cancer Research
39. CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19/T790M/C797S Mutation
    Kenji Kashima, Hiroki Kawauchi, Hiromi Tanimura, Yukako Tachibana, Takashi Chiba, Takuya Torizawa, Hiroshi Sakamoto · 2020 · Molecular Cancer Therapeutics
40. Prognostic Value of the New International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Lung Adenocarcinoma Classification on Death and Recurrence in Completely Resected Stage I Lung Adenocarcinoma
    Jung‐Jyh Hung, Wen‐Juei Jeng, Teh‐Ying Chou, Wen‐Hu Hsu, Kou‐Juey Wu, Biing‐Shiun Huang, Yu–Chung Wu · 2013 · Annals of Surgery
41. The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016
    Tan, Daniel S.W., Yom, Sue S., Tsao, Ming S., Pass, Harvey I., Kelly, Karen, Peled, Nir, Yung, Rex C., Wistuba, Ignacio I., Yatabe, Yasushi, Unger, Michael et al. · 2016 · Journal of Thoracic Oncology
42. Influence of Chemotherapy on <i>EGFR</i> Mutation Status Among Patients With Non–Small-Cell Lung Cancer
    Bai, Hua, Wang, Zhijie, Chen, Keneng, Zhao, Jun, Lee, J. Jack, Wang, Shuhang, Zhou, Qinghua, Zhuo, Minglei, Mao, Li, An, Tongtong et al. · 2012 · Journal of Clinical Oncology
43. Worldwide Frequency of Commonly Detected EGFR Mutations
    Rondell Patrell Graham, Amanda L. Treece, Neal Ian Lindeman, Patricia Vasalos, Mu Shan, Lawrence J. Jennings, David L. Rimm · 2017 · Archives of Pathology & Laboratory Medicine
44. EGFR-mutated lung cancer: a paradigm of molecular oncology
    Zhang, Zhenfeng, Stiegler, Amy L., Boggon, Titus J., Kobayashi, Susumu, Halmos, Balazs · 2010 · Oncotarget
45. Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology – Mainland China Subset Analysis of the PIONEER study
    Yuankai Shi, Junling Li, Shucai Zhang, Mengzhao Wang, Shujun Yang, Ning Li, Gang Wu, Wei Liu, Guoqing Liao, Kaican Cai et al. · 2015 · PLoS ONE
46. PD-L1 Expression as a Predictive Biomarker in Advanced Non-Small-Cell Lung Cancer: Updated Survival Data
    Pedro Nazareth Aguiar, Ramon Andrade de Mello, Peter S Hall, Hakaru Tadokoro, Gilberto De Lima Lopes Jr. · 2017 · Immunotherapy
47. Advances in molecular pathology and therapy of non-small cell lung cancer
    Huang, Qing, Li, Yuanxiang, Huang, Yingdan, Wu, Jingyi, Bao, Wendai, Xue, Chang, Li, Xiaoyu, Dong, Shuang, Dong, Zhiqiang, Hu, Sheng · 2025 · Signal Transduction and Targeted Therapy
48. MET As a Possible Target for Non–Small-Cell Lung Cancer
    Ahad Ali Sadiq, Ravi Salgia · 2013 · Journal of Clinical Oncology
49. SnapShot: Non-Small Cell Lung Cancer
    Rebecca Suk Heist, Jeffrey A. Engelman · 2012 · Cancer Cell
50. Noninvasive Urinary Metabolomic Profiling Identifies Diagnostic and Prognostic Markers in Lung Cancer
    Ewy A. Mathé, Andrew D. Patterson, Majda Haznadar, Soumen Manna, Kristopher W. Krausz, Elise D. Bowman, Peter G. Shields, Jeffrey R. Idle, Philip B. W. Smith, Katsuhiro Anami et al. · 2014 · Cancer Research
51. Targeted therapies for treatment of non‐small cell lung cancer—Recent advances and future perspectives
    Joan Minguet, Katherine Helen Smith, Peter Bramlage · 2015 · International Journal of Cancer
52. Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
    Eric Santoni‐Rugiu, Linea Cecilie Melchior, Edyta Maria Urbanska, Jan Nyrop Jakobsen, Karin de Stricker, Morten Grauslund, Jens Benn Sørensen · 2019 · Cancers
53. Mechanisms of osimertinib resistance and emerging treatment options
    Sabine Schmid, Janice J.N. Li, Natasha B. Leighl · 2020 · Lung Cancer
54. Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials
    Yang, J.C.-H., Sequist, L.V., Zhou, C., Schuler, M., Geater, S.L., Mok, T., Hu, C.-P., Yamamoto, N., Feng, J., O'Byrne, K. et al. · 2016 · Annals of Oncology
55. Genomic heterogeneity of multiple synchronous lung cancer
    Yu Liu, Jianjun J. Zhang, Li Lin, Guangliang Yin, Jianhua Zhang, Shan Zheng, Hannah C. Beird, Ning Wu, Ning Lü, Xizeng Mao et al. · 2016 · Nature Communications
56. Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs
    Qinghua Xu, Fei Zhou, Hui Liu, Tao Jiang, Xuefei Li, Yaping Xu, Caicun Zhou · 2018 · Journal of Thoracic Oncology
57. Pathologic Diagnosis of Advanced Lung Cancer Based on Small Biopsies and Cytology: A Paradigm Shift
    William David Travis, Natasha Rekhtman, Gregory J. Riley, Kim R. Geisinger, Hisao Asamura, Elisabeth M. Brambilla, Kavita Garg, Fred R. Hirsch, Masayuki Noguchi, Charles A. Powell et al. · 2010 · Journal of Thoracic Oncology
58. The pivotal role of pathology in the management of lung cancer.
    Morgan R. Davidson, Adi F. Gazdar, Belinda Edith Clarke · 2013 · Europe PMC (PubMed Central)
59. The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
    Fei Zhou, Haoyue Guo, Yang Xia, Xiuning Le, Daniel S.W. Tan, Suresh S. Ramalingam, Caicun Zhou · 2024 · Nature Reviews Clinical Oncology
60. Inhibition of ALK, PI3K/MEK, and HSP90 in Murine Lung Adenocarcinoma Induced by EML4-ALK Fusion Oncogene
    Zhao Chen, Takaaki Sasaki, Xiaohong Tan, Julián Carretero, Takeshi Shimamura, Danan Li, Chunxiao Xu, Yuchuan Wang, Guillaume Adelmant, Marzia Capelletti et al. · 2010 · Cancer Research
61. ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors
    Johannes M. Heuckmann, Michael Hölzel, Martin L. Sos, Stefanie Heynck, Hyatt Balke‐Want, Mirjam Koker, Martin Peifer, Jonathan M. Weiss, Christine Marie Lovly, Christian Grütter et al. · 2011 · Clinical Cancer Research
62. Genetic Changes in Squamous Cell Lung Cancer: A Review
    Rebecca Suk Heist, Lecia Van Dam Sequist, Jeffrey A. Engelman · 2012 · Journal of Thoracic Oncology
63. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.
    S. Lai, F. Johnson · 2010 · Drug resistance updates
64. Multiple primary lung cancer: A literature review
    Anna Maria Romaszko-Wojtowicz, Anna Doboszyńska · 2018 · Advances in Clinical and Experimental Medicine
65. Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review
    Andrew J. Piper‐Vallillo, Lecia Van Dam Sequist, Zofia Piotrowska · 2020 · Journal of Clinical Oncology
66. Treatment of Stage IV Non-small Cell Lung Cancer
    Mark A. Socinski, Tracey L. Evans, Scott N. Gettinger, Thomas A. Hensing, Lecia Van Dam Sequist, Belinda K. Ireland, Thomas E. Stinchcombe · 2013 · CHEST Journal
67. Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors
    Émmanuelle Vigarios, Joel Brian Epstein, Vincent Sibaud · 2017 · Supportive Care in Cancer
68. Oncogenic mutant forms of EGFR: Lessons in signal transduction and targets for cancer therapy
    Gur Pines, Wolfgang J. Köstler, Yosef Yarden · 2010 · FEBS Letters
69. MET Amplification Status in Therapy-Naïve Adeno- and Squamous Cell Carcinomas of the Lung
    Hans‐Ulrich Schildhaus, Anne Maria Schultheis, Josef Rüschoff, Elke Binot, Sabine Merkelbach‐Bruse, Jana Fassunke, Wolfgang Schulte, Yon‐Dschun Ko, Andreas Schlesinger, Marc Christiaan Allardt Bos et al. · 2014 · Clinical Cancer Research
70. Circulating Tumor DNA Is Effective for the Detection of EGFR Mutation in Non–Small Cell Lung Cancer: A Meta-analysis
    Mantang Qiu, Jie Wang, Youtao Xu, Xiangxiang Ding, Ming Li, Feng Jiang, Lin Xu, Rong H. Yin · 2014 · Cancer Epidemiology Biomarkers & Prevention
71. Cancer Genomics: Technology, Discovery, and Translation
    Ben Tran, Janet Ellen Dancey, Suzanne Kamel‐Reid, John D. McPherson, Philippe Lucien Bedard, Andrew M K Brown, Tong Zhang, Patricia H. Shaw, Nicole Onetto-Pothier, Lincoln David Stein et al. · 2012 · Journal of Clinical Oncology
72. MiR-134/487b/655 Cluster Regulates TGF-β–Induced Epithelial–Mesenchymal Transition and Drug Resistance to Gefitinib by Targeting MAGI2 in Lung Adenocarcinoma Cells
    Kazuhiro Kitamura, Masahiro Seike, Tetsuya Okano, Kuniko Matsuda, Akihiko Miyanaga, Hideaki Mizutani, Rintaro Noro, Yuji Minegishi, Kaoru Kubota, Akihiko Gemma · 2013 · Molecular Cancer Therapeutics
73. Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: A prospective multicenter study in a real-world setting (GFPC study 12-01)
    CHRISTOS CHOUAID, Cécile Dujon, Pascal Dô, I. Monnet, Anne Madroszyk, H. Le Caer, J.B. Auliac, Henri Berard, P. A. Thomas, H. Léna et al. · 2014 · Lung Cancer
74. Lung Cancer in the Era of Precision Medicine
    Katerina A. Politi, Roy S. Herbst · 2015 · Clinical Cancer Research
75. Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients
    Marchetti, Antonio, Palma, John F., Felicioni, Lara, De Pas, Tommaso M., Chiari, Rita, Del Grammastro, Maela, Filice, Giampaolo, Ludovini, Vienna, Brandes, AlbaA., Chella, Antonio et al. · 2015 · Journal of Thoracic Oncology
76. Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?
    Qiao, Meng, Jiang, Tao, Liu, Xinyu, Mao, Shiqi, Zhou, Fei, Li, Xuefei, Zhao, Chao, Chen, Xiaoxia, Su, Chunxia, Ren, Shengxiang et al. · 2021 · Journal of Thoracic Oncology
77. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged nonsmall cell lung cancer and beyond
    Sai‐Hong Ignatius Ou · 2011 · Drug Design Development and Therapy
78. Aflibercept and Docetaxel Versus Docetaxel Alone After Platinum Failure in Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer: A Randomized, Controlled Phase III Trial
    Rodryg Ramlau, В. А. Горбунова, Tudor–Eliade Ciuleanu, Silvia Novello, Mustafa Özgüroğlu, Tuncay Göksel, Clarissa Serodio da Rocha Baldotto, Jaafar Bennouna, Frances A. Shepherd, Solenn Le-Guennec et al. · 2012 · Journal of Clinical Oncology
79. Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers
    Moon‐Young Kim, Jaemoon Koh, Sehui Kim, Heounjeong Go, Yoon Kyung Jeon, Doo Hyun Chung · 2015 · Lung Cancer
80. Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway.
    Cortot, Alexis B., Repellin, Claire E., Shimamura, Takeshi, Capelletti, Marzia, Zejnullahu, Kreshnik, Ercan, Dalia, Christensen, James G., Wong, Kwok-Kin, Gray, Nathanael S., Jänne, Pasi A. · 2013 · Cancer Research
81. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non–Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis
    Bin-Chi Liao, Jih‐Hsiang Lee, Chia‐Chi Lin, Ya‐Fang Chen, Chin‐Hao Chang, Chao‐Chi Ho, Jin‐Yuan Shih, Chong‐Jen Yu, James Chih‐Hsin Yang · 2015 · Journal of Thoracic Oncology
82. Lung cancer in never smokers: Disease characteristics and risk factors
    Athanasios G. Pallis, Konstantinos Nikolaos Syrigos · 2013 · Critical Reviews in Oncology/Hematology
83. International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer: MONET1
    Giorgio V. Scagliotti, Ihor O. Vynnychenko, Keunchil Park, Yukito Ichinose, Kaoru Kubota, Fiona Helen Blackhall, Robert Pirker, Rinat Galiulin, Tudor–Eliade Ciuleanu, Oleksandr Sydorenko et al. · 2012 · Journal of Clinical Oncology
84. Novel therapeutic targets on the horizon for lung cancer
    Wan-Ling Tan, Amit Jain, Angela Maria Takano, Evan William Newell, Narayanan Gopalakrishna Iyer, Wan‐Teck Lim, Eng-Huat Tan, Weiwei Zhai, Axel M. Hillmer, Wai Leong Tam et al. · 2016 · The Lancet Oncology
85. ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors—A systematic review and meta-analysis of real world data
    Filippo Gustavo Dall’Olio, Ilaria Maggio, Maria Massucci, Veronica Mollica, Benedetta Fragomeno, Andrea Ardizzoni · 2020 · Lung Cancer
86. Distinct Clinical Course of EGFR -Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib
    Sandra P. D’Angelo, Yelena Yuriy Janjigian, Nicholas Ahye, Gregory J. Riely, Jamie E. Chaft, Camelia S. Sima, Ronglai Shen, Junting Zheng, Joseph Dycoco, Mark G. Kris et al. · 2012 · Journal of Thoracic Oncology
87. Epidemiology of lung cancer in India: Focus on the differences between non-smokers and smokers: A single-centre experience
    Kumar Prabhash, Vanita Noronha, Rajesh Prabhakar Dikshit, Nirmal Vivek Raut, Amit Joshi, Conjeevaram S. Pramesh, Karishma George, JP Agarwal, Anusheel Munshi · 2012 · Indian Journal of Cancer
88. ALKoma: A Cancer Subtype with a Shared Target
    Hiroyuki Mano · 2012 · Cancer Discovery
89. EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey
    Yatabe, Yasushi, Kerr, Keith M., Utomo, Ahmad, Rajadurai, Pathmanathan, Tran, Van Khanh, Du, Xiang, Chou, Teh-Ying, Enriquez, Ma. Luisa D., Lee, Geon Kook, Iqbal, Jabed et al. · 2015 · Journal of Thoracic Oncology
90. Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mousetrap? A review of the clinical evidence
    Ou, Sai-Hong Ignatius · 2012 · Critical Reviews in Oncology/Hematology
91. A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer
    Tu, Hai-Yan, Ke, E-E, Yang, Jin-Ji, Sun, Yue-Li, Yan, Hong-Hong, Zheng, Ming-Ying, Bai, Xiao-Yan, Wang, Zhen, Su, Jian, Chen, Zhi-Hong et al. · 2017 · Lung Cancer
92. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations
    Ying Cheng, Haruyasu Murakami, Pan‐Chyr Yang, Jianxing He, Kazuhiko Nakagawa, Jin Hyoung Kang, Joo-Hang Kim, Xin Wang, Sotaro Enatsu, Tarun Puri et al. · 2016 · Journal of Clinical Oncology
93. Icotinib versus whole-brain irradiation in patients with EGFR -mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial
    Jin‐Ji Yang, Caicun Zhou, Yi-Sheng Huang, Jifeng Feng, Lu Sun, Yong Song, Cheng Huang, Gang Wu, Li Zhang, Ying Cheng et al. · 2017 · The Lancet Respiratory Medicine
94. Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC
    Scott N. Gettinger, Matthew David Hellmann, Laura Q.M. Chow, Hossein Borghaei, Scott Joseph Antonia, Julie Renee Brahmer, Jonathan Wade Goldman, David E. Gerber, Rosalyn Anne Juergens, Frances A. Shepherd et al. · 2018 · Journal of Thoracic Oncology
95. Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation
    James Chih‐Hsin Yang, Shirish M. Gadgeel, Lecia Van Dam Sequist, Chien-Liang Wu, Vassiliki A. Papadimitrakopoulou, Wu‐Chou Su, Joseph Fiore, Sanatan Saraf, Harry Raftopoulos, Amita Patnaik · 2018 · Journal of Thoracic Oncology
96. Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors
    Jänne, Pasi A., Boss, David S., Camidge, D. Ross, Britten, Carolyn D., Engelman, Jeffrey A., Garon, Edward B., Guo, Feng, Wong, Steven, Liang, Jane, Letrent, Stephen et al. · 2011 · Clinical Cancer Research
97. Clinicopathologic Features of Advanced Squamous NSCLC
    Mark A. Socinski, Coleman K. Obasaju, David R. Gandara, Fred R. Hirsch, Philip Bonomi, Paul A. Bunn, Edward S. Kim, Corey Jay Langer, Ronald B. Natale, Silvia Novello et al. · 2016 · Journal of Thoracic Oncology
98. Randomized Phase III Trial of Gefitinib versus Docetaxel in Non–Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy
    Lee, Dae Ho, Park, Keunchil, Kim, Joo Hang, Lee, Jong-Seok, Shin, Sang Won, Kang, Jin-Hyoung, Ahn, Myung-Ju, Ahn, Jin Seok, Suh, Cheolwon, Kim, Sang-We · 2010 · Clinical Cancer Research
99. Statistical Inference Methods for Two Crossing Survival Curves: A Comparison of Methods
    Huimin Li, Dong Hoon Han, Yawen Hou, Huilin Chen, Zheng Chen · 2015 · PLoS ONE
100. A framework for identification of actionable cancer genome dependencies in small cell lung cancer
     Martin L. Sos, Felix Dietlein, Martin Peifer, Jakob Schöttle, Hyatt Balke‐Want, Christian Müller, Mirjam Koker, André Richters, Stefanie Heynck, Florian Malchers et al. · 2012 · Proceedings of the National Academy of Sciences